Nrf2’s activation increases the levels of immunosuppressive cytokines such as IL-10 and TGF-β, further promoting an environment conducive to tumor progression and resistance to immune checkpoint blockade therapies. The gene discussed is NFE2L2; the disease is neoplasm.